Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX as adjuvant chemotherapy for resectable pancreatic cancer
NCT04084496Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2019
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil in pancreatic cancer (PC), sponsored by Sun Yat-sen University. Started Sep 2019; status: recruiting.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04084496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084496.